US Patent Issued to Nanjing Immunophage Biomedical on Feb. 17 for "Methods and compositions for targeting Tregs using CCR8 inhibitors" (Chinese Inventors)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,552,753, issued on Feb. 17, was assigned to Nanjing Immunophage Biomedical Co. Ltd. (Nanjing, China).

"Methods and compositions for targeting Tregs using CCR8 inhibitors" was invented by Guohuang Fan (Jiangsu, China), Hongyu Yang (Jiangsu, China), Kin Chiu Fong (Jiangsu, China) and Jianfei Wang (Jiangsu, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells."

The patent was filed on Dec. 23, 2022, under Application No. 18/088,447.

*For furthe...